Tovorafenib is a small molecule commercialized by Day One Biopharmaceuticals, with a leading Pre-Registration program in Low-Grade Glioma. According to Globaldata, it is involved in 7 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Tovorafenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Tovorafenib is expected to reach an annual total of $692 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Tovorafenib Overview
Tovorafenib (TAK-580 (MLN2480)) is under development for the treatment of solid tumors such as glioma, melanoma, relapsed pediatric low-grade glioma, Langerhans-cell histiocytosis, craniopharyngioma and malignant glioma. It is administered through oral route. The drug candidate acts by targeting pan-Raf kinases A-Raf, B-Raf and C-Raf. It was also under development for the treatment of solid tumors like metastatic melanoma and non-small cell lung cancer.
See Also:
Day One Biopharmaceuticals Overview
Day One Biopharmaceuticals is a biopharmaceutical company. It discovers and develops drugs for addressing the unmet medical needs of cancers associated with genetic mutations in rapidly accelerated fibrosarcoma (RAF) family kinases. The company investigates its lead product candidate: DAY101 (TAK-580), a pan-RAF inhibitor for the treatment of low-grade glioma and cancers that foster genetic alterations in RAF. It works in partnership with research and the parent advocacy communities to advance the development of medicines for the treatment of various cancer types. Day One Biopharmaceuticals is headquartered in Brisbane, California, the US.
The operating loss of the company was US$146.9 million in FY2022, compared to an operating loss of US$72.7 million in FY2021. The net loss of the company was US$142.2 million in FY2022, compared to a net loss of US$170.6 million in FY2021.
For a complete picture of Tovorafenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
